<?xml version="1.0" encoding="UTF-8"?>
<p>Patients were assessed for response after cycles 1, 2, 3 and 4, and then every 2 cycles during induction and maintenance. Responses were determined according to International Myeloma Working Group criteria (Durie 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0011" ref-type="ref">2006</xref>; Rajkumar 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0040" ref-type="ref">2011</xref>), incorporating the additional categories of near CR (nCR) and minimal response (MR). Bone marrow biopsy and aspirate were obtained prior to starting therapy and presence of minimal residual disease (MRD) was assessed by flow cytometry (sensitivity of available assay: 10
 <sup>−4</sup>) in bone marrow aspirate obtained to confirm a potential CR.
</p>
